logo
New ‘Project Hail Mary' Footage, and Ryan Gosling, Wowed Comic-Con

New ‘Project Hail Mary' Footage, and Ryan Gosling, Wowed Comic-Con

Gizmodo26-07-2025
A few short weeks ago, directors Phil Lord and Chris Miller graced us with an extended first look at their upcoming sci-fi adaptation, Project Hail Mary. The three-minute trailer for a movie not coming out for nine months displayed supreme confidence in the project, and after watching it, you could see why.
So to then bring the film to Hall H at San Diego Comic-Con, along with its iconic star Ryan Gosling, felt almost like too much. We already have this glorious trailer. What more could we see? Well, Lord, Miller, and Gosling were joined by author Andy Weir to talk about all things Project Hail Mary and show a ton of new footage. The crowd ate it up, and now, we're even more excited.
We got over 10 minutes of new footage from the film, all of which was from the first third of the movie. So while it seemed like it was revealing a lot, apparently, it is not. Scene one was, fittingly enough, the first five minutes of the movie. An elaborate claw machine opens a zipper and sucks a tube out of the mouth of Dr. Ryland Grace (Gosling). He's been in deep cryosleep and is disoriented. The machine asks him what 2+2 is, but he can't speak. So each garbled response is called 'incorrect' by the machine. It keeps trying to help him with his awakening, but he's freaking out a bit. He falls face first off the table in an orange sleeping bag. The machine tries to pick him up, but he slips out. He stumbles around the room as the machine tells him he can't move yet and tries to shoot some goo into his mouth to feed him. Eventually he finds his way to a ladder and starts climbing it. On the way up he sees the pods of his friends, but they are all dead. He gets to the top of the ladder, still confused, and says, 'Where am I?' It's then he looks and sees that he's in space. He didn't know and is terrified.
Scene two is back on Earth as Ryland is approached by Eva Stratt (Sandra Hüller) at his school. He doesn't want any part of what she's doing, but she tells him they found a substance on the surface of the sun and need him to look at it. This hard cuts to Ryland in a huge remote lab, in a big suit. He's about 20 feet from Stratt and about 12 military leaders who are all behind glass. 'Am I expendable?' he asks them, at which point they shut off the communications and tell him no, they'd prefer he live. This isn't encouraging. Basically, they want him to look at this sample they took and tell them what it is. This kicks off a sort of mini montage as Ryland starts to get geeky about experimenting. Eventually, he has a eureka moment. 'It's a cell!' he exclaims. This is first contact with an alien species. But, as he's freaking out, he realizes the cell has died.
The third scene is back in space. Ryland is acclimated to it by now and has a sense of his mission. But the ship is stopping. He doesn't know what that means, and when it does, he's put into zero gravity for the first time. He freaks out, starts screaming, and holds on for dear life. Eventually though, he grabs onto a telescope so he looks out at it. He follows a trail in the sky to see what appears to be a smudge. Only, it's not a smudge. It's an alien spaceship that slowly comes next to his craft. He watches in awe and terror.
The final scene in the panel was Ryland connecting with the alien ship. He slowly drops down into a large, rocky tunnel, which dead-ends at a rock wall. He looks through it when two large fingers appear and scare the crap out of him. When he composes himself, he goes back and tries to communicate. Two flat fingers do the almost come-hither motion. As he looks closer, the alien has created a little cutout of a human. 'Is that me?' Ryland asks. It's also made a cutout of his ship, and the alien uses it to try and tell a story visually. Either run back to his ship or run into the alien ship; Ryland can't tell. Eventually though, he just goes back.
Each of the scenes did a great job of being funny and sweet, while also being super intriguing and dramatic. Lord and Miller, with the help of Gosling, really seem to have struck that perfect balance that will bring things into focus. And, with a mix of practical and digital effects bringing the alien, Rocky, to life, we are more than encouraged. We are over the moon.
From the first moment we read Project Hail Mary, through the early look at CinemaCon, and now the Hall H panel, our excitement for the project is only growing. We are ready for this ride.
Written by Drew Goddard, based on the novel by Andy Weir, Project Hail Mary opens March 20.
Want more io9 news? Check out when to expect the latest Marvel, Star Wars, and Star Trek releases, what's next for the DC Universe on film and TV, and everything you need to know about the future of Doctor Who.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline
Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline

Yahoo

time19 minutes ago

  • Yahoo

Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline

Funding will advance Strand's pipeline and mission to bring targeted, next-generation mRNA therapies to patients First-in-human solid tumor Phase 1 data from lead program, STX-001, was recently presented at 2025 ASCO Annual Meeting BOSTON, August 07, 2025--(BUSINESS WIRE)--Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced $153M Series B funding led by Kinnevik, with new investors Regeneron Ventures, ICONIQ, Amgen Ventures, Alderline Group (the family office of Alex Gorsky), JIC-VGI, LG Technology Ventures, and Gradiant Corporation, with continued participation from existing investors including FPV Ventures, Playground Global, Eli Lilly and Company, ANRI, and Potentum. To date, Strand has raised over $250M. As part of the financing, Ala Alenazi, Ph.D., of Kinnevik, will join the company's Board of Directors. The funding will advance Strand's pipeline, led by STX-001, a programmable mRNA therapy that expresses the cytokine interleukin-12 (IL-12) directly from the tumor microenvironment. The company recently announced promising initial Phase 1 clinical data for patients with advanced solid tumors at the 2025 ASCO annual meeting, noting multiple RECIST responses (including cases of complete response and complete metabolic response), multiple cases of prolonged disease stabilization, and a favorable safety profile in treatment-resistant patients. Earlier this year, Strand also presented preclinical data for STX-003, a world-first systemically administrable mRNA therapy with tumor targeting that is programmed to avoid off-target payload delivery (including liver avoidance), showing the first glimpse into the massive potential of their programmable mRNA genetic circuits. Data presented at the 2025 AACR and ASGCT annual meetings demonstrated the candidate's potential to target expression of IL-12 to tumors following systemic administration of the LNP-mRNA drug, creating an effective anti-tumor therapy that was well tolerated. IL-12 is a potent pro-inflammatory cytokine primarily produced by antigen-presenting cells such as macrophages and dendritic cells. IL-12 holds significant promise in cancer immunotherapy due to its robust immunostimulatory effects. STX-001 encodes IL-12 which Strand has designed so that it can reprogram the tumor microenvironment and stimulate a systemic anti-tumor immune response. Unlike traditional mRNA therapies, Strand's approach uses self-replicating mRNA, ensuring localized and durable therapeutic activity. "We believe programmable RNA is the next frontier in therapeutics, and Strand has built the leading platform to unlock it," said Christian Scherrer, Senior Investment Director and Head of Health and Bio at Kinnevik. "Their early clinical data is outstanding, and the systemic delivery capability has the potential to reshape how we treat disease, starting with cancer, with more disease targets on the horizon. We look forward to partnering with founders Jake and Tasuku and the entire team as they move into this next phase of growth." "With support from our investors, we're advancing our vision of developing safe, effective, and accessible therapies through programmable genetic medicines, especially for those patients with few treatment options," said Jake Becraft, PhD, CEO and Co-founder of Strand Therapeutics. "Our initial STX-001 Phase 1 data provides early and strong clinical validation of our platform's capabilities. We have observed systemic immune activation and anti-tumor responses, including responses in non-injected lesions, across multiple tumor types. Now is an exciting period of expansion for our existing clinical work, as well as the exciting breakthrough assets in our pipeline, all with the potential to transform the treatment of cancer and other serious diseases." Strand's proprietary platform for programmable and potent mRNA therapeutics is the first of its kind. Its therapies combine best-in-class engineered next-generation mRNA modalities, such as self-replicating mRNA and circular RNA, with genetically programmed logic circuits, allowing for precise, controlled therapeutic payload delivery directly into the cells/tissues themselves. The novel approach brings the potential to effectively treat cancer and other deadly chronic diseases through its targeted therapies that are scalable, accessible, and expand the treatment landscape for patients desperately in need. About STX-001 STX-001 is an investigational multi-mechanistic, synthetic self-replicating mRNA technology that expresses an IL-12 cytokine for an extended period of time, directly administered to tumors in order to promote immune modulation and antitumor activity. The company received IND clearance from the U.S. Food and Drug Administration (FDA) in December 2023 to initiate a Phase 1/2 clinical trial for STX-001, announced its first patient dosed just before the 2024 ASCO Annual Meeting, and presented the first data of the trial at the 2025 ASCO Annual Meeting. Additional details can be found at using identifier: NCT06249048. About Strand Therapeutics Strand Therapeutics is leading the next generation of programmable mRNA therapies: where synthetic biology meets programmable biology to unlock the full potential of gene regulation and delivery inside the body. Unlike traditional mRNA technologies, Strand's platform programs RNA to think, enabling logic-controlled expression, precision delivery, and unprecedented control over therapeutic outcomes. Born out of MIT and led by world-class synthetic biologists, Strand is building the infrastructure to create medicines that respond to disease signals in real-time. With its computationally-driven design engine, self-amplifying/circular RNA modalities, and mRNA-only genetic circuits, the company is pioneering a new therapeutic modality poised to disrupt immuno-oncology, cell therapy, autoimmune diseases, and beyond. Strand's lead pipeline program, STX-001, is already in the clinic showing unprecedented response rates in late stage "salvage" cancer patients, with multiple patients showing RECIST responses. Strand's modular platform opens a broad horizon of partnership and licensing opportunities. Strand isn't just another mRNA company: it's the operating system for the programmable medicines of tomorrow. Follow us on LinkedIn and on X at @strandtx. View source version on Contacts Media contacts:Karen Sharmaksharma@ Shannia Coleyscoley@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions
Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions

Yahoo

time19 minutes ago

  • Yahoo

Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions

Launch supported by strong assay performance in first milestone readout of the landmark EXPAND clinical trial AUSTIN, Texas, August 07, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal test (NIPT) for inherited conditions. When a pregnant patient is identified as a carrier of a recessive single-gene condition, medical guidelines recommend partner testing in order to determine the risk for the baby to be affected by the condition1; however, in some cases the biological father is unavailable for testing. The Fetal Focus test was designed to address this unmet need. Now if a pregnant patient tests positive with Natera's Horizon™ carrier screen for one of the five most commonly tested genes, and if the father is unavailable for testing, Fetal Focus can screen the fetus directly for that gene by simply analyzing a sample of the mother's blood. Fetal Focus is validated for the analysis of five genes: CFTR (cystic fibrosis), SMN1 (spinal muscular atrophy), HBA1 and HBA2 (alpha-thalassemia), and HBB (beta-hemoglobinopathies, including sickle cell disease). The launch is supported by data from EXPAND, a large, prospective, blinded clinical trial. The study, which was initiated in 2023, has enrolled approximately 1,300 participants to date, reflecting a diverse, multi-ethnic population from leading academic medical centers and maternal fetal medicine clinics. EXPAND is designed to be the defining clinical trial in the category, with all outcomes, including both positive and negative results, confirmed by genetic truth using prenatal or postnatal diagnostic testing. In its first milestone readout (n=101) from EXPAND, the Fetal Focus test demonstrated 91% sensitivity and successfully identified 5/5 fetuses affected by homozygous variants.2,3 Homozygous cases, where the fetus inherits the same condition-causing variant from both parents, are especially challenging to detect. Fetal Focus uses Natera's proprietary LinkedSNP™ technology to improve detection of these cases across diverse populations. "Having access to a noninvasive option like Fetal Focus can provide critical information to support decision-making during pregnancy, especially in situations where partner testing isn't possible," said John Williams, M.D., chief principal investigator for EXPAND and director of reproductive genetics at Cedars-Sinai. "Fetal Focus adds another important offering within our comprehensive reproductive health portfolio – furthering our commitment to launching products that address clinical gaps in care and are supported by rigorous clinical validation," said Sheetal Parmar, M.S., CGC, senior vice president of medical affairs for women's health at Natera. "The EXPAND study has been underway for several years, and we're pleased to release this first milestone readout." References ACOG Committee Opinion #690, Mar 2017. Internal data on file. In EXPAND, the study participants and investigators are blinded to the Fetal Focus™ test results. EXpanding Prenatal Cell Free DNA Screening Across MoNogenic Disorders (EXPAND). Accessed July 2025. About Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and View source version on Contacts Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@ Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@ Sign in to access your portfolio

MGA Entertainment Cooks Up its Newest Innovation Slime Life™— The Makeable, Smashable, Stretchable, Totally Satisfying Food Slime Experience
MGA Entertainment Cooks Up its Newest Innovation Slime Life™— The Makeable, Smashable, Stretchable, Totally Satisfying Food Slime Experience

Yahoo

time19 minutes ago

  • Yahoo

MGA Entertainment Cooks Up its Newest Innovation Slime Life™— The Makeable, Smashable, Stretchable, Totally Satisfying Food Slime Experience

Unbox Hyper-Realistic DIY Kits and Satisfying Fake-Out 'Snacks' for the Ultimate Sensory Play Experience Slime Life Ramen Slime Life Ramen Slime Life Bowl of Choco Cereal Slime Life Bowl of Choco Cereal Slime Life Donuts Pink Icing Round and Jelly Filled LOS ANGELES, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Today MGA Entertainment (MGA), the global toy and entertainment company behind L.O.L. Surprise!™, Little Tikes®, and MGA's Miniverse™, announced the launch of its newest innovation, Slime Life™, offering an ultra-realistic, ASMR-friendly, satisfyingly textured slime experience. Each DIY kit transforms delicious foods into detailed slime creations, empowering kids and collectors to style, smash, and stretch their way through endless creative play. As a constant innovator in the toy industry, MGA recognized the popularity of slime among children and kidults through social media and has been adding slime elements to its other toy lines. In fact, there are more than 480 million posts about slime on TikTok, and the #slime hashtag boasts nearly 15.5 million posts on Instagram. MGA set out to bring a high-quality, food-focused slime experience to kids, kidults, and adults at mass like never before. Slime Life taps into this growing social trend and is bringing a unique sensory experience to households everywhere. Slime Life was inspired by and created in partnership with Slime Community, the wildly popular indie brand started by creator Summer Ames, a creator and beloved mom & pop shop turned viral sensation. MGA worked closely with Slime Community throughout all stages of development of the line. "This was a little, homegrown business that started in our kitchen and to be recognized by an established company like MGA Entertainment is a dream come true," said Summer Ames, founder of Slime Community. "The call from MGA was one of the most memorable moments of my life, and the team has been wonderful to work with every step of the way. The magic of Slime Life goes beyond the slime; it's in the story we created together. MGA didn't have to work with a small business like ours, but they chose to. They saw the value in our passion, our experience, and our love for the craft. That choice made Slime Life not just special, but truly meaningful.' From juicy looking burgers and rainbow cupcakes to creamy PB&J and gooey grilled cheese, Slime Life™ transforms food into playable art letting fans create, style, smash, and stretch their own edible-looking slime creations. Each DIY kit contains vibrant, detailed slime made to look like your favorite foods. Users assemble and style their food dish however they like, becoming the ultimate slime chef. Then they smash it, getting their hands into irresistibly satisfying textures and colors of slime. "We're thrilled to bring MGA's innovative creativity to the trending world of slime, and partnering with Summer Ames from Slime Community makes it even more exciting," said Josh Hackbarth, Chief Marketing Officer at MGA Entertainment. "With a social-first approach, we've created DIY kits that speak directly to creators, kids, and kidults — fun, aesthetic, affordable, and tested to perfection. This is slime done the MGA way." The full 2025 Slime Life lineup includes classic meals and desserts, including: Slime Life Ramen Slime Life Burger Slime Life French Fries Slime Life Nachos Slime Life Cupcake Slime Life Cake Pops Slime Life Macarons Slime Life Donuts - Pink Icing Round & Jelly Filled Slime Life Donuts - Choco Icing Round & Cream Filled Slime Life Grilled Cheese with Chips Slime Life PB&J with Chips Slime Life Ice Cream Cone Slime Life S'mores Slime Life Bowl of Choco Cereal Slime Life Bowl of Fruity Cereal Slime Life™ is available now at Walmart and on and also available October 1, 2025 at Target, Amazon, The MGA Shop, and other retailers. To learn more about this new line, visit About MGA EntertainmentMGA Entertainment is on a mission to inspire imagination and creativity through innovative toys, entertainment, and experiences that transform play into limitless possibilities. As the largest privately held toy and entertainment company in the U.S., MGA is a global leader in designing and delivering world-class consumer products that spark wonder and drive play forward. Headquartered in Los Angeles with offices worldwide, MGA's portfolio spans a dynamic range of original and licensed brands — from toys, dolls, games, and electronics to fashion, home décor, and entertainment content including hit movies and TV series. The company is recognized for its bold approach to storytelling, trendsetting design, and deep commitment to quality. The award-winning MGA family includes fan-favorite brands such as L.O.L. Surprise!™, Little Tikes®, Rainbow High™, Bratz®, MGA's Miniverse™, Yummiland™, CarTuned™, Wonder Factory™, Slime Life™, Ninjombie™, BABY born®, and Zapf Creation®. To learn more, visit and follow MGA on LinkedIn, TikTok, Instagram and Facebook. Contact: Amanda MagalskiFINN Partners on behalf of MGA Entertainmentmga@ Photos accompanying this announcement are available at: A video accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store